BACKGROUND: Serum markers can be important tools for the prognostic classification and the treatment monitoring in cancer patients. Recently, the potential new serum marker YKL-40 has been introduced for patients with malignant melanoma. The purpose of this study was to assess the prognostic value of YKL-40 in stage IV melanoma patients regarding treatment outcome and survival compared to the established markers LDH and serum S-100B and to evaluate their ability to discriminate between different stages of the disease. METHODS: YKL-40, LDH and S-100B were measured in serum samples of 50 patients with stage I/II melanoma and 61 patients with metastatic melanoma before and after treatment. Univariate and multivariate analyses were performed to determine prognostic factors. RESULTS: YKL-40, S-100B and LDH correlated significantly with the stage of disease. In stage IV melanoma patients, only the baseline serum levels of S-100B were significantly associated with treatment response (p=0.031), but not those of LDH (p=0.193) or YKL-40 (p=0.186). We found a strong correlation between treatment response and unchanged or declining S-100B levels over time (p=0.003, OR: 9.52, 95%-CI: 1.87-47.62), but no significant correlation between treatment response and serum changes for LDH (p=0.534) and YKL-40 (p=0.306), respectively. In the Cox Regression analysis, only the serum levels of S-100B proved to have a significant prognostic impact on survival (p<0.0001). CONCLUSION: In melanoma patients, serum levels of YKL-40, S-100B and LDH correlate significantly with the stage of disease. In stage IV melanoma, S100-B significantly correlates with treatment response and survival and is superior to LDH and YKL-40.
BACKGROUND: Serum markers can be important tools for the prognostic classification and the treatment monitoring in cancerpatients. Recently, the potential new serum marker YKL-40 has been introduced for patients with malignant melanoma. The purpose of this study was to assess the prognostic value of YKL-40 in stage IV melanomapatients regarding treatment outcome and survival compared to the established markers LDH and serum S-100B and to evaluate their ability to discriminate between different stages of the disease. METHODS:YKL-40, LDH and S-100B were measured in serum samples of 50 patients with stage I/II melanoma and 61 patients with metastatic melanoma before and after treatment. Univariate and multivariate analyses were performed to determine prognostic factors. RESULTS:YKL-40, S-100B and LDH correlated significantly with the stage of disease. In stage IV melanomapatients, only the baseline serum levels of S-100B were significantly associated with treatment response (p=0.031), but not those of LDH (p=0.193) or YKL-40 (p=0.186). We found a strong correlation between treatment response and unchanged or declining S-100B levels over time (p=0.003, OR: 9.52, 95%-CI: 1.87-47.62), but no significant correlation between treatment response and serum changes for LDH (p=0.534) and YKL-40 (p=0.306), respectively. In the Cox Regression analysis, only the serum levels of S-100B proved to have a significant prognostic impact on survival (p<0.0001). CONCLUSION: In melanomapatients, serum levels of YKL-40, S-100B and LDH correlate significantly with the stage of disease. In stage IV melanoma, S100-B significantly correlates with treatment response and survival and is superior to LDH and YKL-40.
Authors: Sherise D Ferguson; Shivani Bindal; Roland L Bassett; Lauren E Haydu; Ian E McCutcheon; Amy B Heimberger; Jing Li; Barbara J O'Brien; Nandita Guha-Thakurta; Michael T Tetzlaff; Hussein Tawbi; Michael A Davies; Isabella C Glitza Journal: J Neurooncol Date: 2019-03-07 Impact factor: 4.130
Authors: Emanuelle M Rizk; Angelina M Seffens; Megan H Trager; Michael R Moore; Larisa J Geskin; Robyn D Gartrell-Corrado; Winston Wong; Yvonne M Saenger Journal: Am J Clin Dermatol Date: 2020-02 Impact factor: 7.403
Authors: Benjamin Weide; Sabina Richter; Petra Büttner; Ulrike Leiter; Andrea Forschner; Jürgen Bauer; Laura Held; Thomas Kurt Eigentler; Friedegund Meier; Claus Garbe Journal: PLoS One Date: 2013-11-28 Impact factor: 3.240